SEC Filing Analysis: SANGAMO THERAPEUTICS, INC (SGMO)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Institutional investor Wasatch Advisors LP has disclosed a reduction in its stake in Sangamo Therapeutics to 2.1%, falling below the 5% beneficial ownership reporting threshold.
• Market Impact: This filing confirms that a significant institutional holder has been selling its position, which is often interpreted as a bearish signal by the market.

Company Information

Field	Value
Company	SANGAMO THERAPEUTICS, INC
Ticker Symbol	SGMO
CIK	0001001233
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Filer Information

Field	Value
Name	WASATCH ADVISORS LP
CIK	0000814133
Title/Position	Investment Adviser
Relationship	Institutional Owner (formerly >5%)

Transaction Details

This Schedule 13G/A is not a report of a single transaction but an amendment to declare that the filer's ownership has fallen below the 5% threshold.

Field	Value
Form Type	SCHEDULE 13G/A
Event Date	2025-09-30
Security Type	Common Stock
Shares Owned After	6,188,358

Financial Impact Assessment

Ownership Materiality

Metric	Value
Filer's Final Stake	6,188,358 shares
% of Shares Outstanding	2.1% (based on 301,709,485 shares outstanding)
Materiality Assessment	Medium. While not a single large trade, dropping below the 5% ownership threshold is a significant disclosure event, indicating a substantial reduction in the investor's position over time.

Impact Evaluation

• Market Cap Context: Sangamo Therapeutics is a small-cap company with a market capitalization of approximately $170 million. In this context, the actions of institutional investors can have a pronounced impact on stock price and sentiment.
• Ownership Concentration: The filing signals a loss of conviction from a previously significant institutional holder. This change in the ownership structure could be scrutinized by other investors.
• Transaction Significance: The key significance is not a single transaction's value but the crossing of a regulatory threshold. It confirms that Wasatch Advisors has sold a large number of shares over a period of time, reducing its influence and stake in the company.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral to Negative
• Reasoning: The selling pressure that led to this filing has likely already been absorbed by the market. However, the public confirmation of a large investor reducing its stake can create negative sentiment and lead to further selling by other investors who follow institutional moves.

Volume & Sentiment

• Expected Volume Impact: The disclosure itself may cause a short-term increase in trading volume as the market digests the information.
• Sentiment Indicator: Bearish. The exit of a significant institutional investor is generally viewed as a negative signal regarding the company's future prospects.

Investment Insights

Risk Factors

• Loss of Institutional Confidence: This filing demonstrates a reduced conviction from a professional investment firm.
• Potential for Further Selling: Wasatch Advisors still holds over 6 million shares (2.1% of the company). The market may anticipate that they will continue to liquidate the remainder of their position, creating a potential overhang on the stock.

Key Takeaways

1. Ownership Threshold Crossed: Wasatch Advisors is no longer a beneficial owner of more than 5% of Sangamo Therapeutics.
2. Significant Position Reduction: The filing confirms that the investment adviser has been a major seller of SGMO stock.
3. Bearish Signal for Small-Cap: For a company of Sangamo's size, such a move by an institutional holder is a material event that warrants attention from current and potential investors.